MMRF PRESS RELEASES
Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation (MMRF), Named One of TIME Magazine's 100 Most Influential People in the World
April 21, 2011
TIME named Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation (MMRF), to the 2011 TIME 100, the magazine’s annual list of the 100 most influential people in the world. The full list and related tributes appear in the May 2 issue of TIME, available on newsstands on Friday, April 22, and now at TIME.com.
Making the TIME 100 list is an extraordinary honor. I am truly humbled to stand in the presence of my fellow honorees—each and every one an incredible inspiration in their own right,” said Giusti, who was selected for the TIME 100 list for the incredible progress she has made transforming the way medical research and drug development are conducted and, ultimately, dramatically improving the outlook for patients with multiple myeloma, a deadly form of blood cancer, as well as other cancers.
Soon after being diagnosed with multiple myeloma in 1998, Giusti founded the MMRF, which has helped accelerate every significant milestone in the disease. Most notably, the MMRF played a pivotal role in bringing patients four new treatments for myeloma in four years—a track record unparalleled in oncology. Introduction of these treatments, now the standard of care for multiple myeloma, has helped to more than double life expectancy among some patients to almost seven years. Success treating myeloma has led to use of these drugs in many other cancers, including breast cancer, prostate cancer, and lymphoma.
In 2004, Kathy founded the MMRF’s affiliate organization, the Multiple Myeloma Research Consortium (MMRC) to focus on conducting Phase I and Phase II clinical trials of novel compounds. To date, the MMRC has supported the launch of 30 clinical trials of new and combination therapies 60 percent faster than the industry standard, including eight now in late stage clinical development.
The TIME 100, now in its eighth year, recognizes the activism, innovation and achievement of the world’s most influential individuals. As TIME Managing Editor Richard Stengel has said of the list in the past, “The TIME 100 is not a list of the most powerful people in the world, it’s not a list of the smartest people in the world, it’s a list of the most influential people in the world. They’re scientists, they’re thinkers, they’re philosophers, they’re leaders, they’re icons, they’re artists, they’re visionaries. People who are using their ideas, their visions, their actions to transform the world and have an effect on a multitude of people.”? Follow @TIME for updates about the list on Twitter and at Facebook.com/TIME?Hashtag is #TIME100.
About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $160 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States were estimated to be diagnosed with multiple myeloma and approximately 11,000 people died from the disease.